文献速递膀胱癌与上尿路尿路上皮癌

组织学变异对帕博利珠单抗治疗尿路上皮癌患者结局的影响:倾向性评分匹配分析

Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
PubMed 文献 · BJU Int · 2021-07-06

该回顾性研究纳入755例接受帕博利珠单抗治疗的化疗耐药晚期尿路上皮癌患者,其中19.5%存在组织学变异。经倾向性评分匹配后,变异组与纯尿路上皮癌组在客观缓解率、疾病控制率和总生存上无显著差异;但肉瘤样变异患者缓解率和生存更优。

要点

  • 组织学变异不影响帕博利珠单抗的缓解率和总生存。
  • 肉瘤样变异患者客观缓解率、疾病控制率和总生存优于纯尿路上皮癌。
  • 鳞状变异最常见,其缓解率和生存与纯尿路上皮癌相当。

核心结论

  • 组织学变异的存在似乎不影响化疗耐药尿路上皮癌患者接受帕博利珠单抗后的最佳总体缓解或总生存。
  • 肉瘤样变异患者相比纯尿路上皮癌患者获得更有利的缓解和生存率。

研究设计与样本

  • 回顾性分析755例接受帕博利珠单抗治疗的晚期尿路上皮癌患者的医疗记录。
  • 将患者分为纯尿路上皮癌和各组织学变异类型,采用倾向性评分匹配比较最佳总体缓解和总生存。

主要发现

  • 147例(19.5%)患者存在任何组织学变异。
  • 倾向性评分匹配后,任何变异组与纯尿路上皮癌组的客观缓解率(24.5% vs 17.3%,P=0.098)和疾病控制率(36.7% vs 30.2%,P=0.195)无显著差异。
  • 任何变异组与纯尿路上皮癌组的死亡风险相似(HR 0.90,95%CI 0.68-1.20;P=0.482)。
  • 鳞状变异(队列中最常见)的客观缓解率、疾病控制率和总生存与纯尿路上皮癌或非鳞状变异相当。
  • 肉瘤样变异患者(n=19)相比纯尿路上皮癌患者,客观缓解率(36.8%,P=0.031)、疾病控制率(52.6%,P=0.032)和总生存(HR 0.37,95%CI 0.15-0.90;P=0.023)显著更优。

临床怎么用

  • 对于化疗耐药的晚期尿路上皮癌,组织学变异的存在不应排除使用帕博利珠单抗。
  • 肉瘤样变异患者可能从帕博利珠单抗治疗中获得更好的缓解和生存,可考虑积极使用。

局限性

  • 回顾性研究设计。
  • 肉瘤样变异亚组样本量较小(n=19)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the impact of histological variants on survival and response to treatment with pembrolizumab in patients with chemo-resistant urothelial carcinoma (UC). PATIENTS AND METHODS: The medical records of 755 patients with advanced UC who received pembrolizumab were reviewed retrospectively. Patients were classified into pure UC (PUC) and each variant. Best overall response (BOR) and overall survival (OS) were compared between the groups using a propensity score matching (PSM). RESULTS: Overall, 147 (19.5%) patients harboured any histological variant UC (VUC). After PSM, there were no significant differences in the objective response rate (ORR, 24.5% vs 17.3%, P = 0.098) or disease control rate (DCR, 36.7% vs 30.2%, P = 0.195) when comparing patients with any VUC and PUC. Furthermore, any VUC, as compared with PUC, was associated with a similar risk of death (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.68-1.20; P = 0.482). Squamous VUC, which was the most frequent variant in the cohort, had a comparable ORR, DCR and OS as compared with PUC or non-squamous VUC. The patients with sarcomatoid VUC (n = 19) had significantly better ORR (36.8%, P = 0.031), DCR (52.6%, P = 0.032), and OS (HR 0.37, 95% CI 0.15-0.90; P = 0.023) compared to patients with PUC. CONCLUSIONS: The presence of variant histology did not seem to affect BOR or OS after pembrolizumab administration in patients with chemo-resistant UC. The patients with sarcomatoid VUC achieved favourable responses and survival rates compared to PUC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kobayashi M, Narita S, Matsui Y, et al. Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis. BJU Int. 2021. PMID: 34110696. doi:10.1111/bju.15510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。